HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

NSC 224131 (PALA)

inhibitor of aspartate transcarbamylase; bisubstrate ligand; RN refers to (L)-isomer
Also Known As:
PALA; N-(phosphonacetyl)-L-aspartate; N-(phosphonoacetyl)-L-aspartate; NSC 224131, disodium salt; NSC 224131, tetrasodium salt; NSC-224131; N-(phosphonoacetyl)-L-aspartic acid
Networked: 193 relevant articles (18 outcomes, 56 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Montero, Jean-Louis: 2 articles (03/2005 - 10/2003)
2. Whitehead, Robert P: 2 articles (11/2004 - 08/2004)
3. Ardalan, Bach: 2 articles (11/2004 - 08/2004)
4. Abbruzzese, James L: 2 articles (11/2004 - 08/2004)
5. Balcerzak, Stanley P: 2 articles (11/2004 - 08/2004)
6. Macdonald, John S: 2 articles (11/2004 - 08/2004)
7. Benedetti, Jacqueline K: 2 articles (11/2004 - 08/2004)
8. Weill, Jean-Claude: 1 article (10/2015)
9. Reynaud, Claude-Agnès: 1 article (10/2015)
10. Wang, Jin: 1 article (08/2015)

Related Diseases

1. Colorectal Neoplasms (Colorectal Cancer)
2. Neoplasms (Cancer)
3. Carcinoma (Carcinomatosis)
4. Leukemia
10/01/1982 - "Differential effect of N-(phosphonacetyl)-L-aspartate on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors."
02/01/1996 - "Ara-C cytotoxicity to leukemic blast cells from 11 untreated patients with different types of leukemia was only modulated to a small extent by high PALA concentrations in only two cases. "
04/01/1985 - "At the clinically relevant concentration of 1 microM, dipyridamole increased the cytotoxicity of PALA against a melanoma, a colon carcinoma, a promyelocytic leukemia (HL-60), and normal marrow (CFU-GM) in clonogenic assays. "
04/01/1993 - "At the maximum tolerated doses, the antitumor activity in mice bearing advanced colon carcinoma can be summarized as follows: (a) FdUrd is significantly more active than FUra; (b) for both drugs the weekly for 3 weeks i.v. push schedule is superior to the c.i. or i.v. push daily for 4 days schedules; (c) pretreatment with PALA enhances the antitumor activity of FdUrd and FUra and resulted in 95 and 13% complete responses, respectively; (d) long-term survivors with FUra could only be achieved in the presence of PALA; in mice bearing leukemia 1210 cells, FdUrd or FUra with or without PALA exhibited no significant antitumor activity when PALA was administered in a single dose 24 h prior to fluoropyrimidine treatment; and (e) in C-26 and L1210, PALA reduced the pools of CTP and UTP equally, to about 10% of controls with significant difference in their rates of recovery."
08/01/1976 - "PALA, unlike other antimetabolites, was less effective against ascitic leukemias than against two solid tumors, B16 melanoma and Lewis lung carcinoma. "
5. Adenocarcinoma

Related Drugs and Biologics

1. Fluorouracil (Carac)
2. NSC 224131 (PALA)
3. Leucovorin (Folinic Acid)
4. Aspartic Acid (Aspartate)
5. Interferons
6. Thymidine
7. Methylthioinosine
8. Interferon Alfa-2a (Interferon Alfa 2a)
9. pyrimidine
10. 6-Aminonicotinamide (6 Aminonicotinamide)

Related Therapies and Procedures

1. Combination Drug Therapy (Combination Chemotherapy)
2. Drug Therapy (Chemotherapy)
3. Lymph Node Excision (Lymph Node Dissection)
4. Aftercare (After-Treatment)
5. Transplants (Transplant)